Ask AI
ProCE Banner Activity

Update: Debating Optimal Neoadjuvant Therapy and Future Considerations on the Horizon for HR+/HER2- EBC

Slideset Download

Download this slideset for insights on neoadjuvant treatment, along with future considerations for patients with HR+/HER2- early breast cancer.

Released: July 02, 2021

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Artios, Arvinas, AstraZeneca, Atkis Oncology, Avenzo, Bayer, BeOne, Bicycle, BioNTech, Boehringer Ingelheim, Boundless Bio, Bristol Myers Squibb/SystImmune, Celcuity, Circle, Cullinan Oncology, Daiichi Sankyo, Denali, Eisai, Genentech/Roche, Gilead, Jazz, Johnson & Johnson/Ambrx, Launch, Lilly, Menarini/Stemline, Merck, Mersana, Novartis, Olema, Pfizer/SeaGen, Reveal Genomics, Samsung Bioepis, Summit, Tempus, Zuellig; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Genentech/Roche, Gilead, Jazz, Lilly, Menarini/Stemline, Merck, NanoString, Novartis, OncoPep, Pfizer/SeaGen.